SCHEMBL790282

SCHEMBL790282

CS(=O)(=O)Nc1cccnc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.65
ALDH1A1 P00352 5/20 0.58
TP53 P04637 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KEAP1 Q14145 1/20 0.57
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
POLB P06746 2/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GAA P10253 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TSHR P16473 1/20 0.54
PTGS1 P23219 1/20 0.54
PTGS2 P35354 1/20 0.54
LMNA P02545 1/20 0.51
ALPL P05186 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20502487 0.98 NAMPT (0.63) NAMPTALDH1A1TP53TDP1KEAP1
SCHEMBL6739276 0.81 LMNA (0.56) ALDH1A1TP53TDP1KMT2AMEN1
SCHEMBL21602344 0.81 NAMPT (0.50) NAMPTALDH1A1TP53TDP1KMT2A
SCHEMBL7545177 0.80 CA1 (0.57) ALDH1A1TP53TDP1KMT2AMEN1
SCHEMBL28258314 0.80 KMT2A (0.56) NAMPTALDH1A1TP53TDP1KMT2A
SCHEMBL3939566 0.80 PTGS1 (0.54) NAMPTALDH1A1TP53TDP1KMT2A
SCHEMBL19700363 0.79 ALDH1A1 (0.59) ALDH1A1TP53TDP1KMT2AMEN1
SCHEMBL14705314 0.79 ALDH1A1 (0.54) ALDH1A1TP53TDP1KMT2AMEN1
SCHEMBL7079530 0.78 ALDH1A1 (0.57) NAMPTALDH1A1TP53TDP1KMT2A
SCHEMBL28179572 0.78 KMT2A (0.54) NAMPTALDH1A1TP53TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230084927-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF METABOMED LTD. (IL) 2023-03-16 US claimed
US-20040180889-A1 Pin1-modulating compounds and methods of use thereof PINTEX PHARMACEUTICALS, INC. 2004-09-16 US claimed
WO-2003073999-A2 PINI-MODULATING COMPOUNDS AND METHODS OF USE THEREOF PINTEX PHARMACEUTICALS, INC. (US) 2003-09-12 WO claimed
JP-5271191-A None JP disclosed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds PFIZER INC. (US) 2025-10-16 US disclosed
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2024-09-12 US disclosed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed
EP-3099304-B1 CHROMAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF GLAUCOMA MAYO FOUND MEDICAL EDUCATION & RES (US) 2024-07-17 EP disclosed
CN-117643634-A Gold rod nanocomposite with bacterial targeting effect and preparation method and application thereof 贵州医科大学 2024-03-05 CN disclosed
CN-117295717-A LPA receptor antagonists and uses thereof 吉利德科学公司 2023-12-26 CN disclosed
US-5494772-A Heat-sensitive recording materials for infrared-laser recording comprising tricarbocyanine dye having at least two acidic groups FUJI PHOTO FILM CO., LTD. (JP) 1996-02-27 US disclosed
WO-1995000481-A1 PIPERIDIN-1-YL-2,2-DIALKYLPROPANONEARYLSULFONAMIDE DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1995-01-05 WO disclosed
JP-H05271191-A AQUEOUS CHEMILUMINESCENCE SYSTEM AMERICAN CYANAMID CO 1993-10-19 JP disclosed
EP-0548616-A1 Aqueous chemiluminescent systems AMERICAN CYANAMID COMPANY (US) 1993-06-30 EP disclosed
EP-0131302-B1 IMIDAZOLIUM SALTS, INTERMEDIATES THERETO AND THEIR USE SCHERING AKTIENGESELLSCHAFT (DE) 1992-01-29 EP disclosed
US-4766243-A Electrophilic fluorination of aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1988-08-23 US disclosed
US-4689341-A Antiarrhythmic imidazoles SCHERING A.G. (DE) 1987-08-25 US disclosed
US-4613609-A Antiarrhythmic imidazoliums SCHERING A. G. (DE) 1986-09-23 US disclosed
EP-0131302-A2 Imidazolium salts, intermediates thereto and their use SCHERING AKTIENGESELLSCHAFT (DE) 1985-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A NAMPT 1367/4885ALDH1A1 332/4885TP53 2/4885
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF BCL2, BCL2L2, BCL2L1 NAMPT 2670/4885ALDH1A1 3682/4885TP53 87/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 NAMPT 3462/4885ALDH1A1 821/4885TP53 1/4885
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds HRH4, HNMT, NNT NAMPT 26/4885ALDH1A1 2633/4885TP53 740/4885
US-20230084927-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF SLC2A4, SLC2A1, SLC2A2 NAMPT 705/4885ALDH1A1 1014/4885TP53 473/4885
US-20040180889-A1 Pin1-modulating compounds and methods of use thereof PIN1, FKBP14, PIN4 NAMPT 662/4885ALDH1A1 4434/4885TP53 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.